Skip to content
Company Analysis

Alvotech Warrant ALVOW

A comprehensive view of key metrics, scores, and financial health for Alvotech Warrant

Overview of Alvotech

ALVOW NGM
Healthcare Drug Manufacturers - Specialty & Generic
Alvotech (ALVOW), in the Drug Manufacturers - Specialty & Generic industry, last closed at $0.33, about 0.0% overvalued vs fair value, ranked 505/1121 in sector.
$0.33
0.00%
As of April 28, 2026
Previous close • Vol 90d: 62.2%
52-Week Range
Enterprise Value
-
Overall Score
View breakdown
Overall
Growth
Excellent
Profitability
Good
Health
Weak
Efficiency
Fair
Growth
Excellent
Profitability
Good
Health
Weak
Efficiency
Fair
Completeness: 62%
Confidence: 39%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.alvotech.com
HQ Luxembourg
Employees 1,012
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Shares outstanding missing or non-positive

Engine Room Money Flow™

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$489.7M
435.6%%
Gross Profit
$304.4M
538.4%%
R&D Expense
$171.3M
-18.7%%
Operating Income (EBIT)
$-63.6M
87.7%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
35.0%
Fair

High R&D intensity - heavy pipeline investment

Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$194.6M

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
3
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Alvotech Warrant's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
57
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
49
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 81% Coverage
Trade-Off Triangle Visualization A ternary plot showing ALVOW's balance between Growth (53.4%), Profitability (28.3%), and Safety (18.3%). Growth 53% Safety 18% Profitability 28%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

95th percentile vs peers
95
Key Signals
Rev Growth YoY 4.36 95p Revenue CAGR 3Y 1.37 95p
Strengths
  • Growth performance in top 20% of peers (percentile: 95)
  • Rev Growth YoY in top 20% of peers (4.36, 95th percentile)
  • Revenue CAGR 3Y in top 20% of peers (1.37, 95th percentile)
  • Superior capital returns - 2 return metrics above peer median
Risks

No significant risks identified for this axis.

Profitability

50th percentile vs peers
51
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

32th percentile vs peers
33
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Alvotech Warrant.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info